key: cord-1028427-q084zylq authors: Padmanabhan, U.; Mukherjee, S.; Borse, R.; Joshi, S.; Deshmukh, R. title: Phase II Clinical trial for Evaluation of BCG as potential therapy for COVID-19 date: 2020-11-03 journal: nan DOI: 10.1101/2020.10.28.20221630 sha: 5bffa7c37fe95f6fde4a4941f6f01744bf19b963 doc_id: 1028427 cord_uid: q084zylq Bacillus Calmette Guerin (BCG) is widely used in national vaccination programs worldwide. It is accepted that BCG alleviates both pathogen and allergy induced respiratory diseases that could also include Covid-19. To investigate this possibility, we randomly assigned 60 Covid-19 patients, after admission to the hospital with pneumonia and requirement for oxygen therapy in a 1:1 ratio to receive either a single adult dose of intradermal BCG or normal saline with concomitant standard of care (SoC) medications. Primary endpoints were favorable prognosis of Covid-19 as deduced from resolution of pneumonia, viremia and secondary outcome were enumeration of ICU admissions, duration thereof and mortalities. Results Both primary and secondary endpoints were significantly improved in the BCG+SoC group. This could be seen from reduction in oxygen requirement due to Covid-19 associated pneumonia decreasing from day 3-4, improved radiological resolution from day 7-15. There were a total of 6 (10%) adverse events in the study of which 2 deaths and 4 ICU admissions were in SoC group (1 ICU admission culminated in death of the subject) and in contrast only 1 ICU admission in the BCG+SoC group. While there was an increase in Covid-19 specific IgG levels in the BCG+SoC group, there was no evidence of BCG induced cytokine storm in this group. Four patients showed localized inflammatory response at the injection site in the BCG+SoC group. Conclusions BCG+SoC administration resulted in a significantly higher percentage of patients with favorable outcomes than did SoC. A third of the patients were naive for childhood BCG vaccination. This mimicked elderly patients in countries with no universal vaccination policy for BCG. No BCG related adversity was seen in this group. The study shows that BCG is a safe, cost-effective treatment that can be introduced as a standard of care in patients with moderate Covid-19 that can reduce requirement of oxygen supplemented beds and disease burden in low resource countries, with additional long-term benefits of reducing risk for tuberculosis. The novel coronavirus nCoV-19 or 2019-nCoV (severe acute respiratory coronavirus 2 or SARS-CoV-2), has affected more than 10 million people worldwide, resulting in significant mortality and is responsible for the global pandemic COVID-19. The clinical course is variable of COVID-19 is variable with older age and the presence of comorbidities increasing the risk of more severe disease [1] [2] [3] . BacilleCalmette-Guérin (BCG) is a live attenuated strain of the bovine tuberculosis bacillus, Mycobacterium bovis, that is the only WHO recommended vaccine against tuberculosis till date shown to have non-specific protective effects against allergenic and pathogenic respiratory disorders [4] [5] . Miller et al, Hegarty and Dayal et al., 2020 [6-8] show a negative correlation between BCG immunization status of a country and mortalities due to COVID-19. Epidemiological data presented therein that suggested that BCG could be effective against nCoV-19 or SARS-CoV-2. It was the purpose of this study to investigate a direct link between BCG intervention in moderate Covid-19 patients with primary endpoints of reduction in oxygen dependency, faster resolution of COVID-19 symptoms, an evaluation of viremia and favorable outcome for COVID-19. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted November 3, 2020. ; https://doi.org/10.1101/2020. 10.28.20221630 doi: medRxiv preprint The trial was an investigator-initiated, individually randomised, placebo-controlled, double-blind interventional phase II trial to assess the effectiveness and safety of intradermal BCG in adults Eligible Subjects (n=60) were adults; men and non-pregnant women (aged 18-60 years) with COVID-19 admitted to hospital with laboratory-confirmed SARS-CoV-2 infection (as pre RT-PCR), with an interval from symptom onset to enrolment of 12 days or less, oxygen saturation of 94% or less on room air and radiologically confirmed pneumonia. Exclusion criteria included any co-morbidities, immunodeficiency disorders, pregnant and lactating women. Subjects were All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted November 3, 2020. ; https://doi.org/10.1101/2020.10.28.20221630 doi: medRxiv preprint screened and enrolled in multiples of two, so that subjects could be randomized parallely into both arms. Double blind randomization was achieved by on-site physician choosing identically loaded syringes with saline or reconstituted BCG (see Consort Flow Diagram Fig S1, Fig S2 and Protocol in Supp Appendix). Patients were randomly assigned in a 1:1 ratio to the BCG arm (single intradermal adult dose of The study assessments included daily multiple measurements of SpO2, pulse rate and other vital sign measurements, periodic clinical laboratory testing (CBC, serum ferritin, CPK-MB, biochemical parameters) and Chest X rays. Adverse events such as ICU admission, non-invasive ventilation, intubation, death leading to discontinuation of treatment were reported to the IEC and DCGI initially within 24 hours and then reported in detail by 14 days. Blood sampling and nasopharyngeal swabs in VTM for evaluating viremia were collected on days 0, 7 and 15. Clinical data were recorded on paper case record forms and then entered into an electronic database. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted November 3, 2020. ; https://doi.org/10.1101/2020.10.28.20221630 doi: medRxiv preprint Nasopharyngeal swabs were collected in VTM for viral RNA detection and quantification. VTMs were stored at -80 o C until they were thawed for analyses. The viral load was estimated using RT-qPCR as per details in the Supplementary Appendix. Serum levels of IL-6, TNF-alpha, IFN-gamma, IgG and IgM (nCov-19 specific) were evaluated from blood samples of days 0, 7 and 15 using ELISA kit from Krishgen Biosciences and Raybiotech, as per manufacturer's instructions. In general, for analyses between the two major groups in the study BCG+SoC and SoC, median values of data for each group were considered and Mann Whitney or Wilcoxon Signed Rank analyses as stated was employed. Where there were more than 2 groups, Kruskal Wallis analyses was performed. Patients who had not received BCG vaccination (which is part of the Universal vaccination program in India) as neonates, hereinafter referred to as naïve patients, were posthoc analyzed as a separate subgroup. Statistical differences were considered significant when p<0.05. All probabilities are two-tailed. All statistical tests and graphs were performed by GraphPad Prism 5.0 (GraphPad software, San Diego, CA). All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted November 3, 2020. ; https://doi.org/10.1101/2020.10.28.20221630 doi: medRxiv preprint Table 1 outlines the demographic and clinical characteristics of the total of 60 patients who were enrolled in the study, 36 were males (60%) and 24 (40%) were females. Age analyses revealed that patients randomized to receive BCG+SoC (median age = 49 yrs) were older than those who received SoC (median age = 41.5 yrs, p = 0.076, Mann Whitney analyses). About 40% patients were obese/overweight (26/60). Of these 20% (12/30) were obese (9 on BCG+SoC, 3 on SoC) and (12/30) 20% were overweight (4 on BCG+SoC, 8 on SoC). SoC medications were as per the national guidelines and were not contraindicated with concomitant use of BCG (see Fig S3) . Remdesivir was administered to four (4/30, 13.33%) patients on the SoC arm as an emergency care option as specified by ICMR [9] . Four (4/30, 13.33%) patients in the BCG+SoC group showed local inflammatory response to BCG (see Fig S5A) . The SpO2/FiO2 data of subjects in the BCG+SoC and SoC groups were compared (Fig 1A,B (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted November 3, 2020. ; https://doi.org/10.1101/2020.10.28.20221630 doi: medRxiv preprint As per the Fleischner Society consensus statement, the typical CT findings of COVID-19 are bilateral and peripheral predominant ground glass opacities [10] [11] . CXR images were evaluated for the presence and distribution of the following abnormalities hazy increased lung opacity in number of zones involved, hilar abnormalities, cardiomegaly and pleural effusion. As shown in Fig 1C, over a 15 day period, subjects in the BCG+SoC arm showed significant radiological improvement over the SoC arm in concurrence with the improvement seen in oxygen saturation. About a third (19/60, 30%) of the subjects in the study were naïve and had not received BCG vaccination as neonates. Of these 9 (5 males and 4 females) were randomized to the SoC arm and 10 (4 males and 6 females) were in the BCG+SoC arm. Linear regression analyses of the data for SoC(vacc) = 10.76±1.07 (p < 0.001, Kruskal wallis test). Analyses of the age of these subjects indicated that age of naïve subjects [median age = 54.5 yrs (21-60 yrs)] in the study was significantly higher (p = 0.0033, MannWhitney test) than that of All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted November 3, 2020. ; https://doi.org/10.1101/2020.10.28.20221630 doi: medRxiv preprint We checked whether administration of BCG would have an effect on the viral load in patients by estimating the C T values (Supp Fig S6) . Supp Fig S6 A&B show the amplification curves for subjects enrolled from 6th May -15th Jun 2020 and from 15th Jun -5th Aug 2020, respectively. The melt curves in Fig. S6C show a single peak indicating specificity of primers. Shown in Fig Table 1 shows that the number of ICU admissions were 5 out of which 4 patients were on the SoC arm and 1 in the BCG+SoC arm. There were 2 deaths in the SoC arm out of which one was an ICU admission which resulted in death and none on the BCG+SoC arm. Remdesevir was used on emergency basis in India as SoC [9] and was administered to 4 patients on the SoC arm and to 1 subject in the BCG+SoC arm (data of this patient not analyzed, see Fig S1) . All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted November 3, 2020. ; https://doi.org/10.1101/2020.10.28.20221630 doi: medRxiv preprint As shown in Figure 3 (A&B) overall comparison of subjects in SoC and BCG+SoC revealed significantly higher WBC count (p = 0.036), a mild increase in neutrophil count in SoC group and similar lymphocyte count in both groups. Over a 15 day period, the lymphocyte count in both groups showed an increase and the NLR (neutrophil to lymphocyte ratio) showed a larger decrease in BCG+SoC compared to SoC. NLR one of the early risk factors identified for 2019-nCoV severe illness; patients with age ≥ 50 and NLR ≥ 3.13 facilitated severe illness [12] . In our study, the NLR decreased at similar rates in both arms; median NLR was 7.19 (SoC) and 6.28 (BCG+SoC). There were 2 subjects with extremely high N/L ratio: Subject #A, N/L=88 and Subject #B, N/L= 69 (Fig 3G) . In corroboration with reports that NLR is a measure of adverse prognosis of covid-19, both subjects were admitted to ICU; whereas subject #A in the BCG+SoC arm deteriorated to need NIV, subject #B on SoC deteriorated to need NIV, was subsequently intubated and later succumbed to the disease; even though subject #B had a lower N/L ratio compared to subject #A. Comparison of WBC, neutrophil, lymphocyte count in both arms, suggests that part of the increase in WBC count in the SoC arm is due to increase in neutrophil count, which in the BCG+SoC arm is accounted by the lymphocyte count (presumably higher antibody producing B and T cells). Should this hypothesis be true, n-CoV-Sars2 specific IgM and IgG levels should be indicative of the same. Notably the total level of Covid specific IgG levels (Fig 3I & J) in the BCG+SoC arm was higher compared to SoC. However, we did not see detectable levels of n-CoV-Sars2 specific IgM (data not shown). The presence of detectable IgG, but not IgM also corroborates with timelines reported for seroconversion [13] and fairly homogenous population All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted November 3, 2020. ; https://doi.org/10.1101/2020.10.28.20221630 doi: medRxiv preprint in this study. As our supplementary data suggests analyses of platelets, erythrocytes etc did not reveal any significant differences between the two groups ( Fig S8) . Patients with severe COVID-19 show elevated inflammatory markers, including ferritin [12] [13] [14] , IL-6 [15] , which constitute the cytokine storm that has been associated with critical and lifethreatening prognosis. A widely disseminated argument against the use of BCG as a therapy for Covid-19 is that BCG induced immune reaction may aggravate the cytokine storm associated with Covid-19 and worsen Covid19 prognosis [16] [17] . We therefore monitored Ferritin, and evaluated IL-6 levels, TNF-α and IFN-γ levels in patients on day 0, 7 and 15 after enrollment. As shown in Fig 4A&B, [15] , high ferritin levels were also observed in ICU admitted patients in our study (Supp table S4 ). There was no significant increase in serum levels of IL-6 or TNF-α levels in BCG+SoC group over the SoC group (Fig 4C-F) . We also estimated IFN-γ, but did not see detectable levels of IFN-γ in these samples (data not shown). A comparison of biochemical parameters of all the patients inclusive of serum sodium, potassium, Alkaline phosphatase, SGOT, SGPT, Creatinine, Urea, Uric acid, Bilirubin, Total protein and Albumin (Fig S9) revealed significant differences only in 3 parameters sodium, uric acid and bilirubin (Table S3) , none of which were outside the normal reference interval. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted November 3, 2020. ; https://doi.org/10.1101/2020.10.28.20221630 doi: medRxiv preprint Our results indicate that subjects receiving BCG+SoC display a significant improvement in oxygen saturation status within 3-4 days and faster resolution of pneumonia of than subjects receiving SoC thus implicating localized effects in the lung and innate immunity. Such nonspecific effects of BCG that provides immune protection through heterologous mechanisms against diseases other than tuberculosis has also been seen immediately after neonatal vaccination [18] [19] [20] . Several modes of action have been proposed for these acute non-specific effects of BCG immunization: innate immunity 'training' through control on iron homeostasis, induction of receptor expression on NK cells, monocytes so that response to BCG-unrelated antigens is quicker and larger increase in levels of IL-1β, IL-6, IFN-γ and TNF-α are observed which is also accompanied by a shift of metabolism from oxidative phosphorylation to glycolysis [21] [22] [23] . Mice studies indicate that infection with BCG results in acute induction of localized lung immunity through expansion of CD4+, CD8+, and other specific T cells subsets by week 4 that produce IL-6, TNF-α, IFN-γ and systemic increase in IFN-γ levels [24, 25] . These observations are reason for being apprehensive of a cytokine storm induced by BCG and complicating Covid-19 prognosis. As our data shows, the BCG+SoC cohort had lower ferritin levels compared to the SoC group indicating a control on inflammation (see Fig 4) . Thus it appears that, BCG induced an ironwithholding response, as has been speculated as mechanism of innate immunity mediated nonspecific protection in neonates [21, 26] . However, systemic IL-6, TNF-α levels did not significantly differ in both arms indicating absence of any cytokine storm. Levels of IFN-γ were below detection limit over the duration of the study (Fig 4) possibly because of the pulmonary All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted November 3, 2020. ; https://doi.org/10.1101/2020.10.28.20221630 doi: medRxiv preprint zones involved at enrollment, negative correlation of lower IFN-γ levels with lung fibrosis associated with Covid -19 and the fact that interferon response was seen only 4 weeks after BCG administration in a cohort from South India [27] [28] . About 20% of the patients in the study were BCG naïve and they were significantly older than vaccinated patients (Fig S2) . Notably, there were no BCG related adversities seen in naïve subjects, instead the fastest hyopoxia resolution was in naïve subjects on BCG+SoC arm whereas in naïve patients on the SoC arm, hypoxia did not improve even after 12-14 days. Comparison between hypoxia resolution in vaccinated and naïve patients on the SoC arm indicates that BCG vaccination in childhood may have some residual effect in offering protection to pneumonia (see (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted November 3, 2020. To our knowledge this is the first study of the use of BCG as a therapy for Covid-19 that provides a direct comparison between BCG naïve and vaccinated subjects. This is an important takeaway of the study and should pave the way for countries without BCG in their national health policies to introduce BCG as a therapy for Covid-19. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted November 3, 2020. ; https://doi.org/10.1101/2020.10.28.20221630 doi: medRxiv preprint All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted November 3, 2020. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted November 3, 2020. ; https://doi.org/10.1101/2020.10.28.20221630 doi: medRxiv preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted November 3, 2020. (vacc) group, 20 pts, red circles; SoC (naïve) group, 9 pts, blue circles and BCG+SOC (naïve) group, 10 pts, red triangles] as calculated from measured SpO2 for each subject on that corresponding day. Vertical bars represent min-max ranges of medians calculated for that corresponding day. The black lines represent the linear regression lines fitted to the data. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted November 3, 2020. ; https://doi.org/10.1101/2020.10.28.20221630 doi: medRxiv preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted November 3, 2020. ; https://doi.org/10.1101/2020.10.28.20221630 doi: medRxiv preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted November 3, 2020. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted November 3, 2020. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted November 3, 2020. ; https://doi.org/10.1101/2020.10.28.20221630 doi: medRxiv preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted November 3, 2020. ; https://doi.org/10.1101/2020.10.28.20221630 doi: medRxiv preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted November 3, 2020. ; https://doi.org/10.1101/2020.10.28.20221630 doi: medRxiv preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted November 3, 2020. ; https://doi.org/10.1101/2020.10.28.20221630 doi: medRxiv preprint Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study DNA from mycobacterium bovis bacillus Calmette-Guérin (MY-1) inhibits immunoglobulin E production by human lymphocytes Tuberculosis patients with human immunodeficiency virus infection Correlation between universal BCG vaccination policy and reduced morbidity and mortality for COVID-19: an epidemiological study BCG vaccination may be protective against Covid-19 Connecting BCG Vaccination and COVID-19: Additional Data medRxiv 2020 Fleischner Society: Glossary of Terms for Thoracic Imaging COVID-19 pneumonia manifestations at the admission on chest ultrasound, radiographs, and CT: single-center study and comprehensive radiologic literature review Neutrophil-to-Lymphocyte Ratio Predicts Severe Illness Patients with 2019 Novel Coronavirus in the Early Stage Utility of Ferritin, Procalcitonin, and C-reactive Protein in Severe Patients with Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study The potential role of IL-6 in monitoring severe case of coronavirus disease 2019 COVID-19: consider cytokine storm syndromes and immunosuppression No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted Routine vaccinations and child survival: follow up study in Non-specific effects of vaccination on child survival: prospective cohort study in Burkina Faso Non-specific effects of vaccination on child survival? A prospective study in Senegal Heterologous effects of infant BCG vaccination: potential mechanisms of immunity The role of BCG/PPD-activated macrophages in resistance against systemic candidiasis in mice Bacille Calmette-Guerin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes Pulmonary Immune Responses during Intranasal BCG vaccination protects BALB/c mice against virulent Mycobacterium bovis and accelerates production of IFN-gamma in their lungs MRC-International Nutrition Group. The effect of BCG on iron metabolism in the early neonatal period: A controlled trial in Gambian neonates BCG revaccination boosts adaptive polyfunctional Th1/Th17 and innate effectors in IGRA+ and IGRA-Indian adults Lower Circulating Interferon-Gamma Is a Risk Factor for Lung Fibrosis in COVID-19 Patients Enhancement of non-specific resistance to viral infection by muramyldipeptide and its analogs Nonspecific protection of mice against influenza virus infection by local or systemic immunization with Bacille Calmette-Guerin Effects of immunostimulants on resistance of newborn mice to herpes simplex type 2 infection All rights reserved. No reuse allowed without permission.